Design efficiency in dose finding studies

DOI10.1016/S0167-9473(02)00323-7MaRDI QIDQ956828zbMATH OpenOpenAlexFDO

Authors Xavier Paoletti, John O'Quigley, Jean Maccario

Publication date 26 November 2008

Published in Computational Statistics and Data Analysis (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1016/s0167-9473(02)00323-7

zbMATH Keywords

clinical trialsefficiencyoptimalitydose findingphase I designs

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05)

Recommendations

• Optimal designs for dose-finding studies
• Optimal designs for dose finding studies with an active control
• Dose Finding – A Challenge in Statistics
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Adaptive Dc-optimal designs for dose finding based on a continuous efficacy endpoint

Cites work

• scientific article; zbMATH DE number 524373 (Why is no real title available?)
• A Curve‐Free Method for Phase I Clinical Trials
• A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Design and Analysis of Phase I Clinical Trials
• MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION
• Miscellanea. A stopping rule for the continual reassessment method
• Non-parametric optimal design in dose finding studies
• TWO-SAMPLE CONTINUAL REASSESSMENT METHOD

Cited in

(17)

• Prediction Approaches to Sequentially Searching for an Optimal Dose
• Early completion of phase I cancer clinical trials with Bayesian optimal interval design
• A modified Huber loss function for continual reassessment methods in clinical trials
• Non-parametric optimal design in dose finding studies
• Continual reassessment and related dose-finding designs
• Fractional accumulative calibration-free odds (f-aCFO) design for delayed toxicity in phase I clinical trials
• Adaptive clinical trial designs for phase I cancer studies
• Efficiency of bridging between related dose finding studies
• Target toxicity design for phase I dose-finding
• Cumulative cohort design for dose-finding
• Up-and-down designs for dose-finding
• Coherence principles in dose-finding studies
• Performance Measures in Dose‐Finding Experiments
• Robustness of Design in Dose–Response Studies
• Biometric practicesimple benchmark for complex dose finding studies
• Adaptive Bayesian compound designs for dose finding studies
• Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies

This page was built for publication: Design efficiency in dose finding studies

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q956828)